0|chunk|

1|chunk|(0) Comments 2 1 REVIEW Small molecules with antiviral activity against the Ebola virus [v1; ref status: indexed,
1	30	39 molecules	Chemical	CHEBI_25367
1	45	54 antiviral	Chemical	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_25367	CHEBI_22587

2|chunk|The recent outbreak of the Ebola virus in West Africa has highlighted the clear shortage of broad-spectrum antiviral drugs for emerging viruses. There are numerous FDA approved drugs and other small molecules described in the literature that could be further evaluated for their potential as antiviral compounds. These molecules are in addition to the few new antivirals that have been tested in Ebola patients but were not originally developed against the Ebola virus, and may play an important role as we await an effective vaccine. The balance between using FDA approved drugs versus novel antivirals with minimal safety and no efficacy data in humans should be considered. We have evaluated 55 molecules from the perspective of an experienced medicinal chemist as well as using simple molecular properties and have highlighted 16 compounds that have desirable qualities as well as those that may be less desirable. In addition we propose that a collaborative database for sharing such published and novel information on small molecules is needed for the research community studying the Ebola virus. PubMed Abstract | Publisher Full Text 2. Anon. World Health Organization media center. 2014. Reference Source 3. Debing YD, Jochmans J, Neyts J: Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013; 3(2): 217-24. PubMed Abstract | Publisher Full Text 4. Simmons CP, Wolbers M, Nguyen MN, et al.: Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis. 2012; 6(9): e1752. PubMed Abstract | Publisher Full Text | Free Full Text 5. Stadler K, Masignani V, Eickmann M, et al.: SARS--beginning to understand a new virus. Nat Rev Microbiol. 2003; 1(3): 209-18. PubMed Abstract | Publisher Full Text 6. Raj VS, Osterhaus AD, Fouchier RA, et al.: MERS: emergence of a novel human coronavirus. Curr Opin Virol. 2014; 5: 58-62. PubMed Abstract | Publisher Full Text | Free Full Text 7. De Clercq E: Strategies in the design of antiviral drugs. Nat Rev Drug Discov. 2002; 1(1): 13-25. PubMed Abstract | Publisher Full Text 8. De Clercq E: Antivirals and antiviral strategies. Nat Rev Microbiol. 2004; 2(9): 704-20. PubMed Abstract | Publisher Full Text 9. De Clercq E: Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol. 2015; 93(1): 1-10. PubMed Abstract | Publisher Full Text 10. Brown CS, Lee MS, Leung DW, et al.: In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014; 426(10): 2045-58. PubMed Abstract | Publisher Full Text | Free Full Text 11. Han Z, Lu J, Liu Y, et al.: Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol. 2014; 88(13): 7294-306. PubMed Abstract | Publisher Full Text | Free Full Text 12. Opsenica I, Burnett JC, Gussio R, et al.: A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem. 2011; 54(5): 1157-69. PubMed Abstract | Publisher Full Text | Free Full Text 13. Johnson JC, Martinez O, Honko AN, et al.: Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res. 2014; 107: 102-9. PubMed Abstract | Publisher Full Text | Free Full Text 14. Johansen LM, Brannan JM, Delos SE, et al.: FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013; 5(190): 190ra79. PubMed Abstract | Publisher Full Text | Free Full Text 15. Madrid PB, Chopra S, Manger ID, et al.: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013; 8(4): e60579. PubMed Abstract | Publisher Full Text | Free Full Text References PubMed Abstract | Publisher Full Text | Free Full Text 32. Hohman M, Gregory K, Chibale K, et al.: Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today. 2009; 14(5-6): 261-70.
2	107	116 antiviral	Chemical	CHEBI_22587
2	107	122 antiviral drugs	Chemical	CHEBI_36044
2	117	122 drugs	Chemical	CHEBI_23888
2	177	182 drugs	Chemical	CHEBI_23888
2	199	208 molecules	Chemical	CHEBI_25367
2	292	301 antiviral	Chemical	CHEBI_22587
2	319	328 molecules	Chemical	CHEBI_25367
2	360	370 antivirals	Chemical	CHEBI_22587
2	496	500 role	Chemical	CHEBI_50906
2	574	579 drugs	Chemical	CHEBI_23888
2	593	603 antivirals	Chemical	CHEBI_22587
2	698	707 molecules	Chemical	CHEBI_25367
2	1030	1039 molecules	Chemical	CHEBI_25367
2	1301	1311 antivirals	Chemical	CHEBI_22587
2	1713	1716 Nat	Chemical	CHEBI_82508
2	2014	2023 antiviral	Chemical	CHEBI_22587
2	2014	2029 antiviral drugs	Chemical	CHEBI_36044
2	2024	2029 drugs	Chemical	CHEBI_23888
2	2031	2034 Nat	Chemical	CHEBI_82508
2	2039	2043 Drug	Chemical	CHEBI_23888
2	2125	2135 Antivirals	Chemical	CHEBI_22587
2	2140	2149 antiviral	Chemical	CHEBI_22587
2	2162	2165 Nat	Chemical	CHEBI_82508
2	2449	2458 molecules	Chemical	CHEBI_25367
2	2483	2490 protein	Chemical	CHEBI_16541
2	2518	2526 cofactor	Chemical	CHEBI_23357
2	2761	2764 RNA	Chemical	CHEBI_33697
2	2984	2994 neurotoxin	Chemical	CHEBI_50910
2	3006	3011 light	Chemical	CHEBI_30212
2	3069	3072 Med	Chemical	CHEBI_16867
2	3202	3211 Pyridinyl	Chemical	CHEBI_51635
2	3212	3221 imidazole	Chemical	CHEBI_14434
2	3222	3232 inhibitors	Chemical	CHEBI_35222
2	3240	3243 MAP	Chemical	CHEBI_6716
2	3346	3355 Antiviral	Chemical	CHEBI_22587
2	3504	3512 estrogen	Chemical	CHEBI_50114
2	3513	3532 receptor modulators	Chemical	CHEBI_90710
2	3575	3578 Med	Chemical	CHEBI_16867
2	3738	3743 drugs	Chemical	CHEBI_23888
2	3748	3758 inhibitors	Chemical	CHEBI_35222
2	4070	4074 drug	Chemical	CHEBI_23888
2	4086	4090 Drug	Chemical	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_36044
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_25367
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_50906
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_82508
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_22587	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_23888
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_25367
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_50906
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_82508
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_36044	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_25367
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_50906
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_82508
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_23888	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_50906
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_82508
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_25367	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_82508
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_50906	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_16541
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_82508	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_23357
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_16541	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_33697
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_23357	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_50910
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_33697	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_30212
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_50910	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_16867
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_30212	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_51635
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_16867	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_51635	CHEBI_14434
2	CHEBI-CHEBI	CHEBI_51635	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_51635	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_51635	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_51635	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_14434	CHEBI_35222
2	CHEBI-CHEBI	CHEBI_14434	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_14434	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_14434	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_35222	CHEBI_6716
2	CHEBI-CHEBI	CHEBI_35222	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_35222	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_6716	CHEBI_50114
2	CHEBI-CHEBI	CHEBI_6716	CHEBI_90710
2	CHEBI-CHEBI	CHEBI_50114	CHEBI_90710

3|chunk|PubMed Abstract | Publisher Full Text 33. Ekins S, Freundlich JS, Hobrath JV, et al.: Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharm Res. 2014; 31(2): 414-35. PubMed Abstract | Publisher Full Text | Free Full Text 34. Ekins S, Reynolds RC, Kim H, et al.: Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery. Chem Biol. 2013; 20(3): 370-378. PubMed Abstract | Publisher Full Text | Free Full Text 35. Veljkovic V, Loiseau PM, Figadere B, et al.: Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res. 2015; 4: 34. Publisher Full Text 36. Kouznetsova J, Sun W, Martnez-Romero C, et al.: Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes Infect. 2014; 3: e84. Publisher Full Text 37. Long J, Wright E, Molesti E, et al.: Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.
3	177	181 drug	Chemical	CHEBI_23888
3	393	397 Drug	Chemical	CHEBI_23888
3	603	608 drugs	Chemical	CHEBI_23888
3	623	633 inhibitors	Chemical	CHEBI_35222
3	867	872 drugs	Chemical	CHEBI_23888
3	975	984 Antiviral	Chemical	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_22587

